Igras Estera, O'Caoimh Rónán, O'Brien Paul, Power William
J Refract Surg. 2016 Jun 1;32(6):379-84. doi: 10.3928/1081597X-20160317-01.
To evaluate the long-term effectiveness and safety of combined LASIK and small-aperture intracorneal inlay implantation (KAMRA; AcuFocus, Irvine, CA) for the surgical compensation of presbyopia and refractive errors.
Retrospective chart review of all ametropic, presbyopic patients who underwent combined LASIK and KAMRA inlay implantation at a single clinic. Demographic data and preoperative uncorrected and corrected monocular and binocular near and distance visual acuity (UNVA, UDVA, and CDVA) with manifest refractive spherical equivalent (MRSE) were collected and analyzed. All perioperative adverse events were recorded.
In total, 132 patients were available (median age: 56 years; interquartile range (IQR) ± 5; range: 44 to 68 years). Median preoperative MRSE was +1.37± 1.20 diopters (D). The majority (113; 85%) were hypermetropic. Preoperative median UNVA improved from N24 (J13) ±6 to N6 (J5) ±1 by day 1 postoperatively, remaining stable throughout follow-up. At last follow-up, 97% of patients achieved UNVA of N5 (J3) or better. Median UDVA (implanted eye) improved from 20/40 (0.50 ± 0.41 on the decimal chart) preoperatively to 20/25 (0.80 ± 0.13) at month 12. Binocular UDVA was 20/20 in 88%, with CDVA unchanged for 84% at 12 months. No patient lost more than one line of CDVA. MRSE was also stable, albeit +0.25 D off-target refraction (-0.75 D). Two inlays were explanted due to suboptimal adaptation/corneal haze.
The results of this follow-up study show that combined insertion of a small-aperture corneal inlay with LASIK in presbyopic patients improves near vision with a slight compromise in distance vision in the implanted eye. Overall, it appears to be a safe, effective procedure for the treatment of presbyopia. [J Refract Surg. 2016;32(6):379-384.].
评估准分子原位角膜磨镶术(LASIK)联合小切口角膜基质内植入术(KAMRA;AcuFocus公司,加利福尼亚州欧文市)用于手术矫正老花眼和屈光不正的长期有效性和安全性。
对在单一诊所接受LASIK联合KAMRA植入术的所有屈光不正老花眼患者进行回顾性病历审查。收集并分析人口统计学数据以及术前未矫正和矫正后的单眼及双眼近视力和远视力(未矫正近视力、未矫正远视力和矫正远视力)以及明显屈光球镜当量(MRSE)。记录所有围手术期不良事件。
总共纳入132例患者(中位年龄:56岁;四分位间距(IQR)±5;范围:44至68岁)。术前MRSE中位数为+1.37±1.20屈光度(D)。大多数患者(113例;85%)为远视。术前未矫正近视力中位数从术前第1天的N24(J13)±6提高到N6(J5)±1,并在整个随访期间保持稳定。在最后一次随访时,97%的患者未矫正近视力达到N5(J3)或更好。植入眼的未矫正远视力中位数从术前的20/40(小数视力表上为0.50±0.41)提高到术后12个月的20/25(0.80±0.13)。12个月时,88%的患者双眼未矫正远视力为20/20,84%的患者矫正远视力无变化。没有患者矫正远视力下降超过一行。MRSE也保持稳定,尽管有+0.25 D的目标偏离屈光度(-0.75 D)。由于适配不佳/角膜混浊,取出了两枚植入物。
这项随访研究的结果表明,在老花眼患者中LASIK联合小切口角膜基质内植入术可改善近视力,但植入眼的远视力会略有下降。总体而言,这似乎是一种治疗老花眼的安全、有效的手术方法。[《屈光手术杂志》。2016年;32(6):379 - 384。]